A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
A phase 2 trial of WU-CART-007 in acute lymphoblastic leukaemia and non-Hodgkin lymphoma, run by Allotera Therapeutics, now recruiting.
Overview
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex) is a phase 2 interventional study registered as NCT06514794 by Allotera Therapeutics, with 125 participants planned, started 2025-01-31 and due to reach its primary completion in 2026-12-30. Interventions recorded: WU-CART-007.
Similar pages
not linked directly; found by shared links- TrialA Study of CTD402 in T-ALL/LBL Patients
Shares Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia and the tag pipeline.
- TrialAdaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Shares Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia and the tag pipeline.
- TrialSafety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant
Shares Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia and the tag pipeline.
- TrialSafety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Shares Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia and the tag pipeline.
- TrialPhase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialClinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialA Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialMB-105 in Patients With CD5 Positive T-cell Lymphoma
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.